Business members: profile
Genalyte, has developed a revolutionary new multiplex label-free detection technology based on silicon photonic technology exclusively licensed from CalTech. The methodology detects particles, proteins or nucleic acids, with great sensitivity, and across a broad dynamic range. Multiplex quantitative output is already validated at 24-plex, and could be scaled to many hundreds. The system has been demonstrated in serum, and so is compatible with function in complex media.
First generation instruments are being developed for launch into the life science research market in 2012, with plans to develop a follow on 'point of care' diagnostics product.
This system is developed to address the research and diagnostic markets.
- Moderate throughput affinity screening
- Rapid, label-free, multiplexed, immunoassay
- Peptide array for immune response monitoring
- Direct measurement of microRNAs
- Label-free expression profiling
Genalyte is open to working with strategic partners to address specific markets
in the research and diagnostics fields.
11099, North Torrey Pines Rd
|Area of Operation:||BioTech/Lifesciences|
|Company Size:||Small 10-50 employees|
|Type of Company:||Private Limited Company|